Taken together, our study provides compelling evidence for CD8-independent tumor control by human CD4 T cells in vivo and offers a valuable preclinical tool to explore therapeutic strategies to enhance CD4 CTL differentiation and function. The gene discussed is CD8A; the disease is neoplasm.